Fluorescein Sodium and Proparacaine Hydrochloride · FLUORESCEIN SODIUM 2.5 mg/mL; PROPARACAINE HYDROCHLORIDE 5 mg/mL · Solution/ Drops · Ophthalmic · Altaire Pharmaceuticals Inc.
NDC 59390-0205-05 · 1 BOTTLE, DROPPER in 1 CARTON / 5 mL in 1 BOTTLE, DROPPER · UNAPPROVED DRUG OTHER · View full market →
Only one company currently supplies this market — there is no backup if it stumbles. One of its named manufacturing plants, Altaire Pharmaceuticals Inc., failed FDA inspectionwithin the last two years — the agency’s most serious outcome.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Not scored — fragility is computed for NADAC-priced NDCs.
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
No FDA shortage reports for this drug or its presentations.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Altaire Pharmaceuticals Inc. | FLUORESCEIN SODIUM 2.5 mg/mL; PROPARACAINE HYDROCHLORIDE 5 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Fluorescein Sodium and Proparacaine Hydrochloride — NDC 59390-0205-05," retrieved September 3, 2026, https://drugdashboards.com/drug/59390020505.
Free to cite with attribution — see how the data is put together.